CAR T CELL THERAPY
IN INDIA

NexCAR19 is the result of a deliberate collaboration between one of India’s greatest technical universities and its premier cancer institution — designed from the outset to make advanced cell therapy accessible to patients in middle-income countries.

“NexCAR19 at USD 40,000–50,000 versus Kymriah at USD 475,000 in the United States is the most important proof of concept in the global democratisation of advanced cancer therapy.”

• Scientific Origin: IIT Bombay + Tata Memorial Centre

  Professor Rahul Purwar’s lab at IIT Bombay engineered a humanised anti-CD19 scFv — a deliberate departure from the murine sequences in Western products — partnered with Professor Hasmukh Jain’s haematology team at Tata Memorial Centre, the highest-volume blood cancer centre in South Asia.

• Commercial Reality: ImmunoACT

  Founded as an IIT Bombay spin-out in 2018, ImmunoACT built India’s first GMP-compliant CAR T manufacturing facility on the ACTREC campus — co-located with the treating hospital, eliminating international cold-chain costs and reducing vein-to-vein time to 14–21 days.

India’s CAR T programme combines clinical credibility with structural cost advantages that no other country can match for South Asian, East African, and Gulf patients.

• Unmatched Affordability

  NexCAR19 at USD 36,000–42,000 product cost; total programme USD 55,000–75,000 — approximately 8–12% of US pricing. The world’s lowest commercially approved CAR T.

• Domestic Manufacture

  ImmunoACT’s ACTREC facility delivers full Indian manufacturing — lentiviral vector to release testing — eliminating import premiums and reducing vein-to-vein time to 14–21 days.

• Clinical Quality at TMC

  Tata Memorial Centre developed and validated NexCAR19 in a CDSCO-regulated trial; commercial outcomes (73% ORR, 58% CR for DLBCL) match international benchmarks.

• English-Language Care

  All clinical communication, consent, nursing, and discharge documentation in English — no translator needed for international patients from South Asia, East Africa, or the Gulf.

• Geographic & Cultural Access

  Direct daily flights from Dhaka, Kathmandu, Colombo, Karachi, Nairobi, Dubai, and Doha. Familiar food, religious accommodation, and visa pathways tailored for medical travel.

India offers two CAR T options. The choice depends on age, indication, prior treatment history, manufacturing speed required, and budget.

Pivotal trial efficacy and the cost differential that defines India’s CAR T programme.

• 73%ORR for DLBCL (NexCAR19 pivotal trial)
• 80%Remission rate for B-cell ALL
• USD 55KTotal programme cost from (vs USD 480K+ in USA)
• 14–21 daysVein-to-vein time at ACTREC Mumbai

NexCAR19 is approved for the two largest CAR T indications globally; Kymriah extends access for paediatric and young adult ALL patients.

• R/R B-Cell Lymphoma

  DLBCL, PMBCL, transformed follicular lymphoma, and high-grade (double-hit / triple-hit) B-cell lymphoma after ≥2 prior lines including rituximab and anthracycline. NexCAR19 ORR 73%; CR 58%.

• R/R B-Cell ALL (Paediatric)

  Relapsed or refractory B-cell ALL in patients up to 25 years — covered by both NexCAR19 and Kymriah. Kymriah preferred when extensive long-term follow-up data (ELIANA 5-year) influences family decision-making.

• R/R B-Cell ALL (Adult)

  Adult ALL with relapsed or refractory disease — NexCAR19 approved across age groups. CAR T followed by haploidentical SCT at Tata Memorial Centre offers a curative pathway for fit adults.

A 4–6 week sequential process — shorter than China or Western programmes due to ImmunoACT’s on-campus manufacturing.

1. 1

   Pre-Treatment Workup

   CD19 confirmation, PET-CT or bone marrow assessment, organ function, infectious disease screening, and T-cell fitness review at TMC.

2. 2

   Leukapheresis

   T cells collected at TMC using Spectra Optia apheresis system; cells transferred to ImmunoACT facility on the ACTREC campus within minutes.

3. 3

   Manufacturing at ImmunoACT

   Lentiviral transduction, T-cell expansion, GMP quality control, and cryopreservation — 90–95% manufacturing success rate.

4. 4

   Bridging Therapy

   R-GemOx or bendamustine-rituximab for lymphoma; dexamethasone-based for ALL. Indian generic drugs keep bridging cost low.

5. 5

   Lymphodepletion

   Fludarabine + cyclophosphamide for 3 days using Indian generic chemotherapy — standard international protocol at fraction of Western drug cost.

6. 6

   Infusion & Inpatient Monitoring

   Single IV infusion followed by 14–21 days inpatient monitoring at TMC with dedicated CRS/ICANS protocols and tocilizumab biosimilar bedside availability.

NexCAR19 was approved under India’s New Drugs and Clinical Trials Rules 2019 with manufacturing under Schedule M GMP — harmonised with WHO and broadly equivalent in principle to FDA cGMP and EU ATMP standards.

Indian CAR T centres follow ASTCT consensus grading with tocilizumab biosimilar on every bedside — reducing toxicity-management drug costs to a fraction of US pricing.

Beyond commercial NexCAR19 and Kymriah, several Indian academic institutions are conducting investigator-sponsored CAR T trials — expanding access at potentially lower cost.

• AIIMS Delhi

  India’s most prestigious government-sector medical institution operates its own GMP cell therapy facility. Government-sector trials may be conducted at no or very low cost to the patient.

• CMC Vellore

  South India’s most active haematological oncology and allogeneic SCT centre, building CAR T programmes for B-cell ALL with regional accessibility for South Indian, Sri Lankan, and East African patients.

• Apollo, Manipal, HCG

  Private-sector partner network for Kymriah delivery and emerging NexCAR19 expansion. Apollo Hyderabad and Manipal Bangalore have BMT infrastructure suitable for CAR T toxicity management.

• RGCI, JNCH, Regional Centres

  Rajiv Gandhi Cancer Institute Delhi, JNCH Bhopal, and other regional centres are being added to the CDSCO-approved CAR T treatment network — expanding geographic reach across tier-2 and tier-3 cities.

NexCAR19 is India’s first approved CAR T — not its last. ImmunoACT and academic groups are advancing the next generation of products.

• BCMA CAR T for Multiple Myeloma

  ImmunoACT’s next development priority. An Indian BCMA CAR T at NexCAR19-analogous pricing (USD 40,000–60,000) would transform myeloma treatment across South Asia, where the standard imported drugs are unaffordable for most patients.

• Dual-Target CD19+CD22 CAR T

  AIIMS Delhi and IIT Bombay are exploring dual-target constructs to address antigen-loss escape after CD19 CAR T — the dominant ALL relapse mechanism. An Indian dual-target product is anticipated within 3–5 years.

• Solid Tumour CAR T

  Preclinical work at IIT Bombay and NCCS Pune on mesothelin and HER2 targets for gastric, breast, and pancreatic cancer. Clinical translation expected post-2027 — Chinese trials remain the access route in the near term.

• Allogeneic & Armoured Constructs

  Indian academic groups are evaluating off-the-shelf allogeneic and cytokine-armoured CAR T platforms. These programmes are at earlier stages than China’s but follow the same scientific trajectory.

Total programme cost comparison across the four globally available CAR T options — NexCAR19 is the world’s most affordable commercially approved CAR T.

For most South Asian, East African, and Gulf patients, India is the natural CAR T destination. China is preferred when specific products or trials are needed.

End-to-end navigation across eligibility, product selection, TMC coordination, accommodation, and post-treatment follow-up — with escalation pathways to China when India’s current options are not sufficient.

• CAR T Eligibility Pre-Assessment

  We review disease type (DLBCL, ALL), prior treatment history, CD19 expression status, organ function, and performance status against NexCAR19 and Kymriah eligibility criteria before you commit to travel.

• NexCAR19 vs Kymriah Recommendation

  Based on your age, indication, prior treatment, and budget, we recommend the more appropriate product and arrange contact with the relevant centre and clinical team.

• Tata Memorial Centre Coordination

  Initial haematology consultation, leukapheresis scheduling at TMC, and manufacturing initiation at ImmunoACT — with priority routing for international patients.

• Bridging Therapy & Logistics

  Coordination between TMC haematologists and your home oncologist for bridging therapy in your home country during the manufacturing wait, plus accommodation and travel logistics for the 4–6 week treatment visit.

• Post-CAR T Care & Escalation Pathway

  Written post-CAR T protocol, Indian-sourced IVIG for B-cell aplasia, ongoing TMC–home haematologist liaison, and pre-arranged escalation to Chinese CD22 / dual-target trials if CD19-negative relapse occurs.

20 dedicated support pages covering NexCAR19, Kymriah, regulatory standards, cost breakdowns, indications, and access pathways.

Frequently Asked Questions

Answers to the questions every patient and family should ask before committing to CAR T cell therapy in India.